ArticleFrontiers in immunology2025

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report.

Jingjing Chai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.